Source: European journal of preventive cardiology. Unidade: FM
Subjects: COGNIÇÃO, HIPERCOLESTEROLEMIA, CRIANÇAS, ARTERIOSCLEROSE, SISTEMA NERVOSO CENTRAL
ABNT
SANTOS FILHO, Raul Dias dos et al. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. European journal of preventive cardiology, v. 31, n. 3, p. 302-310, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58820. Acesso em: 10 nov. 2024.APA
Santos Filho, R. D. dos, Ruzza, A., Wang, B., Maruff, P., Schembri, A., Bhatia, A. K., et al. (2024). Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. European journal of preventive cardiology, 31( 3), 302-310. doi:10.1093/eurjpc/zwad332NLM
Santos Filho RD dos, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, Pierre JS. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment [Internet]. European journal of preventive cardiology. 2024 ; 31( 3): 302-310.[citado 2024 nov. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58820Vancouver
Santos Filho RD dos, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, Pierre JS. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment [Internet]. European journal of preventive cardiology. 2024 ; 31( 3): 302-310.[citado 2024 nov. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58820